Department of Biochemistry, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.
Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin 300384, China.
Cells. 2022 Dec 1;11(23):3869. doi: 10.3390/cells11233869.
Microglial activation and subsequent pathological neuroinflammation contribute to diabetic retinopathy (DR). However, the underlying mechanisms of microgliosis, and means to effectively suppress pathological microgliosis, remain incompletely understood. Peroxisome proliferator-activated receptor alpha (PPARα) is a transcription factor that regulates lipid metabolism. The present study aimed to determine if PPARα affects pathological microgliosis in DR. In global mice, retinal microglia exhibited decreased structural complexity and enlarged cell bodies, suggesting microglial activation. Microglia-specific conditional (PCKO) mice showed decreased retinal thickness as revealed by optical coherence tomography. Under streptozotocin (STZ)-induced diabetes, diabetic PCKO mice exhibited decreased electroretinography response, while diabetes-induced retinal dysfunction was alleviated in diabetic microglia-specific -transgenic (PCTG) mice. Additionally, diabetes-induced retinal pericyte loss was exacerbated in diabetic PCKO mice and alleviated in diabetic PCTG mice. In cultured microglial cells with the diabetic stressor 4-HNE, metabolic flux analysis demonstrated that ablation caused a metabolic shift from oxidative phosphorylation to glycolysis. deficiency also increased microglial STING and TNF-α expression. Taken together, these findings revealed a critical role for PPARα in pathological microgliosis, neurodegeneration, and vascular damage in DR, providing insight into the underlying molecular mechanisms of microgliosis in this context and suggesting microglial PPARα as a potential therapeutic target.
小胶质细胞的激活及随后的病理性神经炎症导致了糖尿病性视网膜病变(DR)。然而,小胶质细胞增生的潜在机制以及有效抑制病理性小胶质细胞增生的方法仍不完全清楚。过氧化物酶体增殖物激活受体α(PPARα)是一种调节脂质代谢的转录因子。本研究旨在确定 PPARα 是否影响 DR 中的病理性小胶质细胞增生。在全局 敲除(KO)小鼠中,视网膜小胶质细胞表现出结构复杂性降低和细胞体增大,提示小胶质细胞激活。小胶质细胞特异性条件性 敲除(PCKO)小鼠的视网膜厚度通过光相干断层扫描显示减少。在链脲佐菌素(STZ)诱导的糖尿病中,糖尿病 PCKO 小鼠的视网膜电图反应降低,而糖尿病诱导的视网膜功能障碍在糖尿病小胶质细胞特异性 -过表达(PCTG)小鼠中得到缓解。此外,糖尿病诱导的视网膜周细胞丢失在糖尿病 PCKO 小鼠中加重,而在糖尿病 PCTG 小鼠中得到缓解。在具有糖尿病应激物 4-HNE 的培养小胶质细胞中,代谢通量分析表明, 缺失导致从氧化磷酸化到糖酵解的代谢转变。 缺乏还增加了小胶质细胞 STING 和 TNF-α的表达。综上所述,这些发现揭示了 PPARα 在 DR 中的病理性小胶质细胞增生、神经退行性变和血管损伤中的关键作用,为该背景下小胶质细胞增生的潜在分子机制提供了新的见解,并提示小胶质细胞 PPARα 可能成为一种潜在的治疗靶点。